1-(4-fluorophenyl)-2(1H,3H)-imidazolone | 155431-17-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(4-fluorophenyl)-2(1H,3H)-imidazolone
• 英文别名: 1-(4-fluorophenyl)imidazoline-2-one；3-(4-fluorophenyl)-1H-imidazol-2-one
• CAS: 155431-17-7
• 化学式: C₉H₇FN₂O
• 分子量: 178.166
• InChiKey: RXYOCHHQYYIEIB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-fluorophenyl)-2(1H,3H)-imidazolone 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.5h， 生成 1-[(1R,2R)-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-(4-fluorophenyl)-2(1H,3H)-imidazolone
  参考文献：
  名称：

  Optically Active Antifungal Azoles. VIII. Synthesis and Antifungal Activity of 1-((1R,2R)-2-(2,4-Difluoro- and 2-Fluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)-3-(4-substituted phenyl)-2(1H,3H)-imidazolones and 2-Imidazolidinones.

  摘要：

  新的光学活性抗真菌唑类化合物，1-[(1R, 2R)-2-(2, 4-二氟和2-氟苯基)-2-羟基-1-甲基-3-(1H-1, 2, 4-三唑-1-基)丙基]-3-(4-取代苯基)-2(1H, 3H)-咪唑酮（1, 2）和2-咪唑烷酮（3, 4），是通过立体选择性方式从(1S)-1-[(2R)-2-(2, 4-二氟和2-氟苯基)-2-氧烷基]乙醇（15, 16）制备的。化合物1-4在体外和体内对白色念珠菌表现出强效的抗真菌活性，并且在体外对多种真菌具有广泛的抗真菌谱。此外，咪唑烷酮3b-e和4d, e被发现对烟曲霉具有极强的抑制生长活性。

  DOI：

  10.1248/cpb.47.351
• 作为产物：
  描述：

  1-(2,2-二乙氧基-乙基)-3-(4-氟-苯基)-脲 在 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 48.0h， 生成 1-(4-fluorophenyl)-2(1H,3H)-imidazolone
  参考文献：
  名称：

  Optically Active Antifungal Azoles. VIII. Synthesis and Antifungal Activity of 1-((1R,2R)-2-(2,4-Difluoro- and 2-Fluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)-3-(4-substituted phenyl)-2(1H,3H)-imidazolones and 2-Imidazolidinones.

  摘要：

  新的光学活性抗真菌唑类化合物，1-[(1R, 2R)-2-(2, 4-二氟和2-氟苯基)-2-羟基-1-甲基-3-(1H-1, 2, 4-三唑-1-基)丙基]-3-(4-取代苯基)-2(1H, 3H)-咪唑酮（1, 2）和2-咪唑烷酮（3, 4），是通过立体选择性方式从(1S)-1-[(2R)-2-(2, 4-二氟和2-氟苯基)-2-氧烷基]乙醇（15, 16）制备的。化合物1-4在体外和体内对白色念珠菌表现出强效的抗真菌活性，并且在体外对多种真菌具有广泛的抗真菌谱。此外，咪唑烷酮3b-e和4d, e被发现对烟曲霉具有极强的抑制生长活性。

  DOI：

  10.1248/cpb.47.351

文献信息

• OXAZOLINE DERIVATIVES
  申请人：Galley Guido

  公开号：US20110112080A1

  公开（公告）日：2011-05-12

  The invention relates to compounds of formula I wherein the definitions of X, R and R 1 are as defined herein. The compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  该发明涉及公式I中的化合物，其中X、R和R1的定义如本文所述。公式I中的化合物对痕量胺相关受体（TAARs）有良好的亲和力，特别是对TAAR1。这些化合物可用于治疗抑郁症、焦虑障碍、躁郁症、注意力缺陷多动障碍（ADHD）、与压力相关的障碍、精神分裂症等精神障碍、帕金森病等神经疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用和代谢性障碍，如进食障碍、糖尿病、糖尿病并发症、肥胖、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病。
• Production of Di or tri-azolyl substituted 5-keto azole compounds
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05466820A1

  公开（公告）日：1995-11-14

  An azole compound represented by the formula (I): ##STR1## wherein Ar is a substituted phenyl group; R.sup.1 and R.sup.2 independently are a hydrogen atom or a lower alkyl group, or R.sup.1 and R.sup.2 may combine together to form a lower alkylene group; R.sup.3 is a group bonded through a carbon atom; R.sup.4 is a hydrogen atom or an acyl group; X is a nitrogen atom or a methine group; and Y and Z independently are a nitrogen atom or a methine group which may optionally be substituted with a lower alkyl group, or a salt thereof, which is useful for prevention and therapy of fungal infections of mammals as antifungal agent.

  一种以式子（I）表示的唑类化合物：##STR1## 其中Ar是一个取代的苯基；R.sup.1和R.sup.2分别是氢原子或较低的烷基基团，或R.sup.1和R.sup.2可以结合形成较低的烷基烷基基团；R.sup.3是通过碳原子连接的基团；R.sup.4是氢原子或酰基基团；X是氮原子或甲基基团；Y和Z分别是氮原子或甲基基团，可以选择性地用较低的烷基基团取代，或其盐，用作哺乳动物真菌感染的预防和治疗的抗真菌剂。
• Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents
  申请人：PFIZER INC.

  公开号：EP0060610A1

  公开（公告）日：1982-09-22

  Derivatives of 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole and of (+)enantiomeric, mixtures of (+) and (-)-enantiomeric or (±)racemic 2,3,4,4a,5,9b-hexahydro-4a, 9b-trans-1H-pyrido[4,3-b]indole, substituted at the 5-position with an aryl group and at the 2-position with a carbonylaminoalkyl group or an aminoalkyl group, are neuroleptic agents useful in the treatment of certain psychoses and neuroses.

  2,3,4,5-四氢-1H-吡啶并[4,3-b]吲哚和(+)对映体的衍生物、(+)和(-)对映体的混合物或(±)外消旋2,3,4,4a,5,9b-六氢-4a,9b-反式-1H-吡啶并[4,3-b]吲哚的衍生物，在5位被芳基取代，在2位被羰基氨基烷基或氨基烷基取代，是治疗某些精神病和神经官能症的神经抑制剂。
• Azole compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0567982B1

  公开（公告）日：1998-07-01
• TREATMENT OF DEVELOPMENTAL DISORDERS WITH IMIDAZOLONE DERIVATIVES
  申请人：Ovid Therapeutics Inc.

  公开号：US20180344745A1

  公开（公告）日：2018-12-06

  Methods of treating developmental disorders such as Angelman syndrome, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Childhood Disintegrative Disorder, Rett syndrome, Landau-Kleffner Syndrome, Prader-Willi Syndrome, Tardive Dyskinesia, a seizure disorder and/or Williams Syndrome with a compound of formula 1 or a pharmaceutically acceptable salt thereof, wherein X, R 1 , R 2 , m and n have the meanings set forth in the specification, are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of the developmental disorder.